Skip to main content
Erschienen in: Der Internist 3/2017

13.02.2017 | Arterielle Hypertonie | CME

Diagnostik und Therapie der chronischen Nierenerkrankung

verfasst von: Prof. Dr. M. Girndt

Erschienen in: Die Innere Medizin | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Chronische Nierenschäden sind an einer Verminderung der glomerulären Filtrationsrate oder an einer Proteinurie erkennbar. Quantitativ wichtigste Ursachen der chronischen Nierenschädigung sind die diabetische Nephropathie und Folgeschäden der arteriellen Hypertonie. Therapeutisch ist zunächst zu prüfen, ob eine spezifische Therapie der Grunderkrankung möglich und indiziert ist. In allen Fällen, auch wenn spezifische Behandlungen zu spät kommen, ist eine progressionsverzögernde Therapie erforderlich. Chronische Nierenschäden neigen zur Progression, d. h. zu einer Verschlechterung auch in Abwesenheit des primären Schädigungsmechanismus. Die Progression ist verzögerbar, die wichtigsten Maßnahmen sind die Blutdrucktherapie, Proteinuriereduktion und Vermeidung weiterer Noxen. Folgeerkrankungen wie Linksherzhypertrophie, Gefäßkalzifizierung und Anämie sind heute pathophysiologisch besser verstanden, aber nur bedingt therapierbar. Eine Urämie muss durch Nierenersatztherapie vermieden werden.
Literatur
1.
Zurück zum Zitat KDIGO (2013) Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1CrossRef KDIGO (2013) Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3:1CrossRef
3.
Zurück zum Zitat Girndt M et al (2016) Prävalenz der eingeschränkten Nierenfunktion. Bevölkerungsrepräsentative Studie von 2008–2011 zur Gesundheit Erwachsener in Deutschland (DEGS1). Dtsch Arztebl 113:85–91 Girndt M et al (2016) Prävalenz der eingeschränkten Nierenfunktion. Bevölkerungsrepräsentative Studie von 2008–2011 zur Gesundheit Erwachsener in Deutschland (DEGS1). Dtsch Arztebl 113:85–91
4.
Zurück zum Zitat Titze S et al (2015) Disease burden and risk profile in referred patients with moderate chronic kidney disease: Composition of the German Chronic Kidney Disease (GCKD) cohort. Nephrol Dial Transplant 30:441–451CrossRefPubMed Titze S et al (2015) Disease burden and risk profile in referred patients with moderate chronic kidney disease: Composition of the German Chronic Kidney Disease (GCKD) cohort. Nephrol Dial Transplant 30:441–451CrossRefPubMed
5.
Zurück zum Zitat Eriksen BO, Ingebretsen OC (2006) The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age. Kidney Int 69:375–382CrossRefPubMed Eriksen BO, Ingebretsen OC (2006) The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age. Kidney Int 69:375–382CrossRefPubMed
6.
Zurück zum Zitat Ishani A et al (2006) Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol 17:1444–1452CrossRefPubMed Ishani A et al (2006) Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol 17:1444–1452CrossRefPubMed
7.
Zurück zum Zitat Orth SR, Hallan SI (2008) Smoking: A risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients – absence of evidence or evidence of absence? Clin J Am Soc Nephrol 3:226–236CrossRefPubMed Orth SR, Hallan SI (2008) Smoking: A risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients – absence of evidence or evidence of absence? Clin J Am Soc Nephrol 3:226–236CrossRefPubMed
8.
Zurück zum Zitat Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, Woodward M, MacMahon S, Turnbull F, Hillis GS, Chalmers J, Mant J, Salam A, Rahimi K, Perkovic V, Rodgers A (2016) Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. The Lancet 387(10017):435–443 Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, Woodward M, MacMahon S, Turnbull F, Hillis GS, Chalmers J, Mant J, Salam A, Rahimi K, Perkovic V, Rodgers A (2016) Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. The Lancet 387(10017):435–443
9.
Zurück zum Zitat Cushman WC et al (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362:1575–1585CrossRefPubMed Cushman WC et al (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362:1575–1585CrossRefPubMed
10.
Zurück zum Zitat Lewis EJ et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–860CrossRefPubMed Lewis EJ et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851–860CrossRefPubMed
11.
Zurück zum Zitat Troyanov S et al (2004) Idiopathic membranous nephropathy: Definition and relevance of a partial remission. Kidney Int 66:1199–1205CrossRefPubMed Troyanov S et al (2004) Idiopathic membranous nephropathy: Definition and relevance of a partial remission. Kidney Int 66:1199–1205CrossRefPubMed
12.
Zurück zum Zitat Kent DM et al (2007) Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 18:1959–1965CrossRefPubMed Kent DM et al (2007) Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 18:1959–1965CrossRefPubMed
13.
Zurück zum Zitat Menon V et al (2009) Effect of a very low-protein diet on outcomes: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis 53:208–217CrossRefPubMed Menon V et al (2009) Effect of a very low-protein diet on outcomes: long-term follow-up of the Modification of Diet in Renal Disease (MDRD) Study. Am J Kidney Dis 53:208–217CrossRefPubMed
14.
Zurück zum Zitat de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM (2009) Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 20:2075–2084CrossRefPubMedPubMedCentral de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM (2009) Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 20:2075–2084CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Weisbord SD, Palevsky PM (2008) Prevention of contrast-induced nephropathy with volume expansion. Clin J Am Soc Nephrol 3:273–280CrossRefPubMed Weisbord SD, Palevsky PM (2008) Prevention of contrast-induced nephropathy with volume expansion. Clin J Am Soc Nephrol 3:273–280CrossRefPubMed
16.
Zurück zum Zitat Baigent C et al (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet 377:2181–2192CrossRefPubMedPubMedCentral Baigent C et al (2011) The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial. Lancet 377:2181–2192CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Pfeffer MA et al (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019–2032CrossRefPubMed Pfeffer MA et al (2009) A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361:2019–2032CrossRefPubMed
18.
Zurück zum Zitat Keith DS et al (2004) Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164:659–663CrossRefPubMed Keith DS et al (2004) Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164:659–663CrossRefPubMed
19.
Zurück zum Zitat Go AS et al (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305CrossRefPubMed Go AS et al (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296–1305CrossRefPubMed
20.
Zurück zum Zitat Paoletti E et al (2005) Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis 46:320–327CrossRefPubMed Paoletti E et al (2005) Left ventricular hypertrophy in nondiabetic predialysis CKD. Am J Kidney Dis 46:320–327CrossRefPubMed
22.
Zurück zum Zitat Scialla JJ, Wolf M (2014) Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol 10:268–278CrossRefPubMed Scialla JJ, Wolf M (2014) Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol 10:268–278CrossRefPubMed
23.
Zurück zum Zitat Block GA et al (2015) A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3–5. Am J Kidney Dis 65:728–736CrossRefPubMed Block GA et al (2015) A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3–5. Am J Kidney Dis 65:728–736CrossRefPubMed
24.
Zurück zum Zitat Wolf M (2010) Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 21:1427–1435CrossRefPubMed Wolf M (2010) Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 21:1427–1435CrossRefPubMed
25.
26.
Zurück zum Zitat Naylor KL et al (2014) The three-year incidence of fracture in chronic kidney disease. Kidney Int 86:810–818CrossRefPubMed Naylor KL et al (2014) The three-year incidence of fracture in chronic kidney disease. Kidney Int 86:810–818CrossRefPubMed
27.
Zurück zum Zitat KDIGO (2012) Clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2:279CrossRef KDIGO (2012) Clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2:279CrossRef
28.
Zurück zum Zitat Cooper BA et al (2010) A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med 363:609–619 Cooper BA et al (2010) A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med 363:609–619
29.
Zurück zum Zitat Robinski M, Mau W, Wienke A, Girndt M (2016) The Choice of Renal Replacement Therapy (CORETH) project: dialysis patients’ psychosocial characteristics and treatment satisfaction. Nephrol Dial Transplant doi:10.1093/ndt/gfv464 Robinski M, Mau W, Wienke A, Girndt M (2016) The Choice of Renal Replacement Therapy (CORETH) project: dialysis patients’ psychosocial characteristics and treatment satisfaction. Nephrol Dial Transplant doi:10.​1093/​ndt/​gfv464
31.
Zurück zum Zitat Struijk DG (2015) Peritoneal Dialysis in Western Countries. Kidney Dis (Basel) 1:157–164CrossRef Struijk DG (2015) Peritoneal Dialysis in Western Countries. Kidney Dis (Basel) 1:157–164CrossRef
32.
Zurück zum Zitat Robinski M, Mau W, Wienke A, Girndt M (2016) Shared decision-making in chronic kidney disease: A retrospection of recently initiated dialysis patients in Germany. Patient Educ Couns 99:562–570CrossRefPubMed Robinski M, Mau W, Wienke A, Girndt M (2016) Shared decision-making in chronic kidney disease: A retrospection of recently initiated dialysis patients in Germany. Patient Educ Couns 99:562–570CrossRefPubMed
33.
Zurück zum Zitat Wolfe RA et al (1999) Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341:1725–1730CrossRefPubMed Wolfe RA et al (1999) Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341:1725–1730CrossRefPubMed
Metadaten
Titel
Diagnostik und Therapie der chronischen Nierenerkrankung
verfasst von
Prof. Dr. M. Girndt
Publikationsdatum
13.02.2017
Verlag
Springer Medizin
Erschienen in
Die Innere Medizin / Ausgabe 3/2017
Print ISSN: 2731-7080
Elektronische ISSN: 2731-7099
DOI
https://doi.org/10.1007/s00108-017-0195-2

Weitere Artikel der Ausgabe 3/2017

Der Internist 3/2017 Zur Ausgabe

Schwerpunkt: Internistische Intensivmedizin: Akute Blutungen

Hämoptoe

Kongresse des BDI

Kongresse des BDI

Schwerpunkt: Internistische Intensivmedizin: Akute Blutungen

Massive Urogenitalblutung

Schwerpunkt: Internistische Intensivmedizin: Akute Blutungen

Akute Blutung im oberen Gastrointestinaltrakt